Improvement of growth and food utilization by human recombinant growth hormone in uremia.

Mehls O, Ritz E, Hunziker EB, Eggli P, Heinrich U, Zapf J

Kidney international1 Jan 1988Cited by 88 (Europe PMC)

PMID3352160DOI10.1038/ki.1988.7PepBankPUB-03352160

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH increased weight gain versus vehicle (27.0 versus 11.6 g, P less than 0.01).
In plain wordsIn uremic rats, human GH increased weight gain compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
IncreaseWeight gain in uremic rats
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Body weight · Metabolic and weight
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Measurements
Weight gain
27 g
GH
Weight gain
11.6 g
vehicle
Source sentences
Summary
Compared to uremic rats infused with vehicle, infusion of GH significantly (P less than 0.01) improved growth; that is, it increased gain of weight (delta 27.0 +/- 7.7 g vs. 11.6 +/- 4.9 g) and length (delta 1.8 +/- 0.3 cm vs. 1.12 +/- 0.44 cm) in ad libitum fed uremic rats.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216001
02AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH increased length gain versus vehicle (1.8 versus 1.12 cm, P less than 0.01).
In plain wordsIn uremic rats, human GH increased length gain compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
IncreaseLength gain in uremic rats
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Linear growth · Musculoskeletal
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Measurements
Length gain
1.8 cm
GH
Length gain
1.12 cm
vehicle
Source sentences
Summary
Compared to uremic rats infused with vehicle, infusion of GH significantly (P less than 0.01) improved growth; that is, it increased gain of weight (delta 27.0 +/- 7.7 g vs. 11.6 +/- 4.9 g) and length (delta 1.8 +/- 0.3 cm vs. 1.12 +/- 0.44 cm) in ad libitum fed uremic rats.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216002
03AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH increased food utilization ratio to 0.146 versus 0.065 g weight gain per g food intake with vehicle.
In plain wordsIn uremic rats, human GH increased weight gain per food intake compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
IncreaseFood utilization ratio in uremic rats
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Measurements
Food utilization ratio
0.146 g weight gain per g food intake
GH
Food utilization ratio
0.065 g weight gain per g food intake
vehicle
Source sentences
Summary
This was accompanied by increased food utilization ratio (0.146 vs. 0.065 g weight gain per g food intake).
3 context sentences(design, population, supporting numbers)
Summary · context
Compared to uremic rats infused with vehicle, infusion of GH significantly (P less than 0.01) improved growth; that is, it increased gain of weight (delta 27.0 +/- 7.7 g vs. 11.6 +/- 4.9 g) and length (delta 1.8 +/- 0.3 cm vs. 1.12 +/- 0.44 cm) in ad libitum fed uremic rats.
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216003
04AnimalAnimal study (in vivo)Efficacy outcome
In pairfed control rats, human GH increased growth versus solvent infusion.
In plain wordsIn pairfed control rats, human GH increased growth compared with solvent infusion.
Peptide
HGH (somatotropin)
Outcome
IncreaseGrowth in pairfed controls
Study
ratn: not reported in source
Pairfed sham-operated female Sprague-Dawley rats
Comparator
Vehicle infusion
Outcome group
Linear growth · Musculoskeletal
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
A similar increment of growth and food utilization ratio was also observed in GH versus solvent infused controls, either pairfed as for the uremic animals or fed ad libitum.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216004
05AnimalAnimal study (in vivo)Efficacy outcome
In pairfed control rats, human GH increased food utilization ratio versus solvent infusion.
In plain wordsIn pairfed control rats, human GH increased food utilization compared with solvent infusion.
Peptide
HGH (somatotropin)
Outcome
IncreaseFood utilization in pairfed controls
Study
ratn: not reported in source
Pairfed sham-operated female Sprague-Dawley rats
Comparator
Vehicle infusion
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
A similar increment of growth and food utilization ratio was also observed in GH versus solvent infused controls, either pairfed as for the uremic animals or fed ad libitum.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216005
06AnimalAnimal study (in vivo)Efficacy outcome
In freely fed control rats, human GH increased growth versus solvent infusion.
In plain wordsIn freely fed control rats, human GH increased growth compared with solvent infusion.
Peptide
HGH (somatotropin)
Outcome
IncreaseGrowth in ad libitum controls
Study
ratn: not reported in source
Ad libitum-fed sham-operated female Sprague-Dawley rats
Comparator
Vehicle infusion
Outcome group
Linear growth · Musculoskeletal
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
A similar increment of growth and food utilization ratio was also observed in GH versus solvent infused controls, either pairfed as for the uremic animals or fed ad libitum.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216006
07AnimalAnimal study (in vivo)Efficacy outcome
In freely fed control rats, human GH increased food utilization ratio versus solvent infusion.
In plain wordsIn freely fed control rats, human GH increased food utilization compared with solvent infusion.
Peptide
HGH (somatotropin)
Outcome
IncreaseFood utilization in ad libitum controls
Study
ratn: not reported in source
Ad libitum-fed sham-operated female Sprague-Dawley rats
Comparator
Vehicle infusion
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
A similar increment of growth and food utilization ratio was also observed in GH versus solvent infused controls, either pairfed as for the uremic animals or fed ad libitum.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216007
08AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH did not completely restore normal growth.
In plain wordsIn uremic rats, human GH did not completely restore normal growth.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedRestoration of normal growth
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Normal growth
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Despite administration of GH, growth was not completely restored to normal in uremic animals.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216008
09AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH infusion did not significantly increase circulating immunoreactive IGF I.
In plain wordsIn uremic rats, human GH infusion did not significantly increase circulating IGF I compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
No significant changeCirculating IGF I in uremic rats
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Circulating immunoreactive IGF I was not significantly increased by GH infusion in either uremic animals or controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216009
10AnimalAnimal study (in vivo)Efficacy outcome
In control rats, human GH infusion did not significantly increase circulating immunoreactive IGF I.
In plain wordsIn control rats, human GH infusion did not significantly increase circulating IGF I compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
No significant changeCirculating IGF I in controls
Study
ratn: not reported in source
Sham-operated female Sprague-Dawley rats
Comparator
Vehicle infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Circulating immunoreactive IGF I was not significantly increased by GH infusion in either uremic animals or controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216010
11AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH infusion increased longitudinal tibial growth rate.
In plain wordsIn uremic rats, human GH infusion increased lengthwise tibial growth compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
IncreaseLongitudinal tibial growth rate
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Histological analyses of the proximal tibia showed increased rate of longitudinal growth, as evaluated by tetracyclin-labeling, and increased volumetric density of primary spongiosa with unchanged width of primary spongiosa trabecules when GH was infused in uremic animals.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216011
12AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, human GH infusion increased volumetric density of primary spongiosa.
In plain wordsIn uremic rats, human GH infusion increased primary spongiosa density compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
IncreasePrimary spongiosa volumetric density
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Histological analyses of the proximal tibia showed increased rate of longitudinal growth, as evaluated by tetracyclin-labeling, and increased volumetric density of primary spongiosa with unchanged width of primary spongiosa trabecules when GH was infused in uremic animals.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216012
13AnimalAnimal study (in vivo)Efficacy outcome
In uremic rats, primary spongiosa trabecular width remained unchanged with human GH infusion.
In plain wordsIn uremic rats, human GH infusion did not change primary spongiosa trabecular width compared with vehicle.
Peptide
HGH (somatotropin)
Outcome
No significant changePrimary spongiosa trabecular width
Study
ratn: not reported in source
Female Sprague-Dawley rats with subtotal nephrectomy
Comparator
Vehicle infusion
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.4 IU/day · subcutaneous osmotic minipump · 14 daysAs given in this study (rat).
Source sentences
Summary
Histological analyses of the proximal tibia showed increased rate of longitudinal growth, as evaluated by tetracyclin-labeling, and increased volumetric density of primary spongiosa with unchanged width of primary spongiosa trabecules when GH was infused in uremic animals.
2 context sentences(design, population, supporting numbers)
Summary · context
We compared growth rate, food conversion ratio and morphology of the growth zone in female Sprague-Dawley rats with subtotal nephrectomy or sham operation.
Summary · context
Both groups were either given vehicle or 1.4 IU/day recombinant human growth hormone (GH) by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14 or 20 days, respectively.
Report a problemFND-0335216013

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.